Translocation and mutant ROS kinase in human non-small cell lung carcinoma

Patent metadata

Field	Value
Publication number	US-11761005-B2
Application number	US-202016838265-A
Country	US
Kind code	B2
Filing date	Apr 2, 2020
Priority date	Jan 20, 2006
Publication date	Sep 19, 2023
Grant date	Sep 19, 2023

Abstract

In accordance with the invention, a novel gene translocation, (4p15, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in a fusion proteins combining part of Sodium-dependent Phosphate Transporter Isoform NaPi-3b protein (SLC34A2) with Proto-oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The SLC34A2-ROS fusion protein is anticipated to drive the proliferation and survival of a subgroup of NSCLC tumors. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of the new fusion protein enables new methods for determining the presence of these mutant ROS kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.

First claim

What is claimed is:

1. A composition, comprising
a biological sample of from a human having cancer, and
a nucleic acid reagent comprising a detectably labeled nucleic acid probe,
wherein the nucleic acid probe hybridizes to a polynucleotide encoding a Sodium-Dependent Phosphate Transporter Isoform NaPi-3b protein (SLC34A2)-Proto-Oncogene Tyrosine Protein Kinase ROS precursor (ROS) fusion polypeptide, and
wherein the SLC34A2-ROS fusion polypeptide has ROS kinase activity, and comprises an amino acid sequence which comprises the N-terminal amino acid sequence of SLC34A2 as set forth in residues 1-126 of SEQ ID NO: 5 and the ROS kinase domain as set forth in residues 1945-2222 of SEQ ID NO: 7.

2. The composition of claim 1 , wherein the cancer is lung cancer.

3. The composition of claim 2 , wherein the lung cancer is a non-small cell lung cancer (NSCLC).

4. The composition of claim 3 , wherein the biological sample is a lung cancer tissue biopsy.

5. The composition of claim 2 , wherein the biological sample is a lung cancer tissue biopsy.

6. The composition of claim 1 , wherein the SLC34A2-ROS fusion polypeptide comprises
the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 3.

7. The composition of claim 1 , wherein the SLC34A2-ROS fusion polynucleotide comprises SEQ ID NO: 2 or SEQ ID NO: 4.

8. The composition of claim 1 , wherein the nucleic acid probe comprises break-apart probes that are specific to the ROS locus.

9. The composition of claim 8 , wherein the break-apart probes are fluorescently labeled.

10. The composition of claim 1 , wherein the biological sample is a tumor biopsy.

Assignees

• Cell Signaling Technology Inc

Inventors

• Guo Ailan
• Possemato Anthony

Classifications

• G01N33/5758

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• G01N33/5752

  of the lungs · CPC title

• C07K14/47 Primary

  from mammals · CPC title

• C12N15/1137 Primary

  against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title

• C07K14/82

  Translation products from oncogenes · CPC title